Anebulo Pharmaceuticals, Inc. (ANEB)

OTCMKTS · Delayed Price · Currency is USD

0.3300

0.00 (0.00%)

Jul 28, 2026, 9:32 AM EST

Anebulo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	6.82	4.92	4.76	6.18	3.87	1.34
Research & Development	4.9	4.3	3.55	5.6	2.96	2.27
Operating Income	-9.1	-9.22	-8.31	-11.78	-6.83	-3.61
Interest Income	1.42	1.12	0.25	0.09	0.01	0
Interest Expense	-0.3	-0.38	-0.15	-	-	-0.01
Other Non-Operating Income (Expense)	-0	-0	0.01	-0.04	-0	-26.63
Total Non-Operating Income (Expense)	1.12	0.74	0.11	0.05	0.01	-26.64
Pretax Income	-7.98	-8.48	-8.2	-11.73	-6.83	-30.25
Net Income	-7.98	-8.48	-8.2	-11.73	-6.83	-30.25
Net Income Attributable to Preferred Dividends	-	-	-	-	-	8.21
Net Income to Common	-7.98	-8.48	-8.2	-11.73	-6.83	-38.46
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	41	34	26	25	23	14
Shares Outstanding (Diluted)	41	34	26	25	23	14
Shares Change	56.19%	30.97%	2.98%	7.41%	71.49%	13.44%
EPS (Basic)	-0.19	-0.25	-0.32	-0.47	-0.29	-2.83
EPS (Diluted)	-0.19	-0.25	-0.32	-0.47	-0.29	-2.83
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Free Cash Flow	-5.84	-6.35	-8.09	-9.68	-5.44	-4.87
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.14	-0.19	-0.31	-0.39	-0.23	-0.36
EBITDA	-8.81	-8.84	-8.16	-11.78	-6.83	-3.61
EBIT	-9.1	-9.22	-8.31	-11.78	-6.83	-3.61